Evidence map›Paper›PMID 39112486›Full record

ArticleNature communications2024

Author Correction: dsRNAi-mediated silencing of PIAS2beta specifically kills anaplastic carcinomas by mitotic catastrophe.

Hongli Gong, Shu Tian, Hao Ding, Lei Tao, Li Wang, Jie Wang, Tian Wang, Xiaohui Yuan, Yu Heng, Ming Zhang and 5 more

Erratum issuedAbstract readPublished Erratum
In one paragraph

Article in Nature communications, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

15 authors.

Hongli Gong *ENT institute and Department of Otorhinolaryngology, Eye & ENT Hospital, Fudan University, Shanghai, 200031, China.
Shu Tian *Department of Radiation Oncology, Eye & ENT Hospital, Fudan University, Shanghai, 200031, China.
Hao DingDepartment of Radiation Oncology, Eye & ENT Hospital, Fudan University, Shanghai, 200031, China.
Lei TaoENT institute and Department of Otorhinolaryngology, Eye & ENT Hospital, Fudan University, Shanghai, 200031, China.
Li WangDepartment of Radiation Oncology, Eye & ENT Hospital, Fudan University, Shanghai, 200031, China.
Jie WangDepartment of Radiation Oncology, Eye & ENT Hospital, Fudan University, Shanghai, 200031, China.
Tian WangDepartment of Radiation Oncology, Eye & ENT Hospital, Fudan University, Shanghai, 200031, China.
Xiaohui YuanENT institute and Department of Otorhinolaryngology, Eye & ENT Hospital, Fudan University, Shanghai, 200031, China.
Yu HengENT institute and Department of Otorhinolaryngology, Eye & ENT Hospital, Fudan University, Shanghai, 200031, China.
Ming ZhangENT institute and Department of Otorhinolaryngology, Eye & ENT Hospital, Fudan University, Shanghai, 200031, China.
Yong ShiENT institute and Department of Otorhinolaryngology, Eye & ENT Hospital, Fudan University, Shanghai, 200031, China.
Chengzhi XuENT institute and Department of Otorhinolaryngology, Eye & ENT Hospital, Fudan University, Shanghai, 200031, China.
Chunping WuENT institute and Department of Otorhinolaryngology, Eye & ENT Hospital, Fudan University, Shanghai, 200031, China.
Shengzi WangDepartment of Radiation Oncology, Eye & ENT Hospital, Fudan University, Shanghai, 200031, China. shengziwang@fudan.edu.cn.
Liang ZhouENT institute and Department of Otorhinolaryngology, Eye & ENT Hospital, Fudan University, Shanghai, 200031, China. zhoulent@126.com.ORCID http://orcid.org/0000-0002-8588-2959

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Identifiers

PMID39112486
PMCPMC11306402

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.